Proximagen Initiates Phase I Clinical Trial of PRX167700

Oral Vascular Adhesion Protein-1 antagonist for the treatment of inflammation in rheumatoid arthritis and psoriasis

02-Mar-2012 - Proximagen Group plc announced that it had commenced dosing in a Phase I clinical trial of PRX167700, a Vascular Adhesion Protein-1 (VAP-1) antagonist, for the treatment of inflammation in rheumatoid arthritis (RA) and psoriasis.Proximagen’s PRX167700 is an oral drug candidate that is expected to ...

Proximagen and Altacor sign Collaborative Research and Development Agreement for Proximagen’s 5HT2c programme in Glaucoma

25-Nov-2011 - Proximagen Group plc and Altacor Limited announced that they have signed a Collaborative Research and Development Agreement. Under the terms of the Agreement Altacor will undertake the research and development of PRX00933, the lead compound from Proximagen’s 5HT2c programme, to treat glaucoma. ...

Lundbeck and Proximagen Sign Strategic Partnership Agreement

H. Lundbeck A/S and Proximagen Group plc

04-Oct-2011 - H. Lundbeck A/S and Proximagen Group plc announced that they have entered into a Strategic Partnership Agreement. The Agreement is designed to formalise a partnership between the two companies, a partnership in which Lundbeck and Proximagen will jointly apply their expertise in CNS drug ...

Proximagen signs Sale and Purchase Agreement for sabcomeline

05-Aug-2010 - Proximagen Group plc announced that it has signed a Sale and Purchase Agreement with BrainCells Inc. (BCI) for Proximagen’s sabcomeline programme. Under the terms of the Agreement, BCI will pay Proximagen an up-front fee and milestone payments together worth up to $51 million, as well as a ...

Proximagen enters into a Collaboration Agreement with the NIH for a Phase II clinical trial on naluzotan

08-Jul-2010 - Proximagen Group plc announced that it has signed a Collaboration Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) in the United States. Under the terms of the CRADA, NINDS will fully ...